Atlas Trials

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Clinical trial NCT04105972 · COMPLETED

Trial details

NCT number
NCT04105972
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2019-10-03
Primary completion
2020-07-24
Enrollment
176

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.